Provider Briefing: Acetaminophen/Butalbital Supply in 2026

Acetaminophen/Butalbital/Caffeine — widely recognized by the former brand name Fioricet — remains one of the most commonly prescribed treatments for tension-type headaches. However, intermittent supply disruptions that began around 2020 have continued into 2026, creating challenges for both prescribers and patients.

This briefing provides an overview of the current shortage status, the factors driving it, prescribing implications, cost and access considerations, and resources to support your patients.

Shortage Timeline

Butalbital-containing products have experienced periodic supply disruptions for several years:

• 2020-2021: Initial supply chain disruptions linked to pandemic-era manufacturing slowdowns and raw material sourcing challenges
• 2022-2023: Consolidation among generic manufacturers reduced the number of available suppliers. The brand-name product Fioricet was fully discontinued.
• 2024-2025: Intermittent shortages continued, with availability varying significantly by region and by pharmacy chain vs. independent pharmacy
• 2026 (current): Supply remains inconsistent. The medication is not continuously listed on the FDA's official drug shortage database but is frequently reported as unavailable at point of sale.

The pattern has been one of rolling availability — periods of adequate supply followed by regional stockouts lasting days to weeks.

Prescribing Implications

The ongoing supply issues create several important considerations for prescribers:

Regulatory Status

Acetaminophen/Butalbital/Caffeine (without codeine) is not a federally scheduled controlled substance, which simplifies prescribing compared to alternatives like Fiorinal (Aspirin/Butalbital/Caffeine, Schedule III) or Fioricet with Codeine (Schedule III). However, some states impose additional controls on butalbital-containing products — verify your state's regulations.

Dependence and Medication Overuse

Butalbital carries a meaningful risk of physical dependence and medication overuse headache (MOH). When patients face supply disruptions, there is a risk of:

• Abrupt discontinuation leading to withdrawal symptoms (anxiety, tremor, seizures in severe cases)
• Patients stockpiling medication when available, potentially leading to overuse
• Patients seeking the medication from multiple prescribers

Consider discussing a tapering plan or transition strategy with patients who use the medication frequently (more than 10 days per month).

Prescribing for Availability

When writing prescriptions for Acetaminophen/Butalbital:

• Specify generic substitution permitted to maximize fill options
• Note that both tablet and capsule formulations exist — if one is unavailable, the other may be in stock
• Consider writing for common strengths: 325mg/50mg/40mg (most widely available) or 300mg/50mg/40mg

Current Availability Picture

Availability varies significantly by pharmacy type and geography:

• Large chain pharmacies (CVS, Walgreens, Rite Aid): Most frequently affected by stockouts. Centralized purchasing may limit flexibility when suppliers experience disruptions.
• Independent pharmacies: Generally better positioned to source medication from multiple wholesalers. Many independent pharmacists actively seek alternative suppliers during shortages.
• Mail-order pharmacies: May have more consistent supply due to larger inventory buffers, but availability still varies.

Directing patients to pharmacy availability tools like Medfinder for Providers can help streamline the process of locating pharmacies with current stock.

Cost and Access Considerations

Cost remains a factor for many patients, particularly those without insurance or with high-deductible plans:

• Average retail price: Approximately $88 for 30 tablets of generic Acetaminophen/Butalbital/Caffeine
• Discount card pricing: $26 to $40 for 30 tablets through programs like SingleCare or GoodRx
• Insurance coverage: Generally covered as a Tier 1 or Tier 2 generic. Some plans may require step therapy (trial of OTC analgesics first) or prior authorization.

No manufacturer savings programs exist for the generic, as the brand Fioricet has been discontinued. Patient assistance programs through organizations like NeedyMeds and RxAssist may help uninsured or underinsured patients. For a patient-facing resource on cost, see our guide on saving money on Acetaminophen/Butalbital.

Alternative Therapies to Consider

When Acetaminophen/Butalbital is unavailable or when transitioning patients to other options, consider the following:

For Tension-Type Headaches

• NSAIDs (Ibuprofen 400-800mg, Naproxen 250-500mg): First-line for episodic tension-type headache. Widely available and cost-effective.
• Acetaminophen (1000mg): Appropriate for patients who cannot take NSAIDs. Less effective than combination products but readily available OTC.
• Muscle relaxants (Cyclobenzaprine, Tizanidine): May address the muscle tension component, though evidence for headache specifically is limited.

For Migraine or Mixed Headache

• Triptans (Sumatriptan, Rizatriptan, Eletriptan): First-line for moderate-to-severe migraine. Well-studied, widely available as generics.
• Gepants (Ubrogepant/Ubrelvy, Rimegepant/Nurtec): CGRP receptor antagonists for acute migraine. Newer agents without vasoconstrictive effects.
• Lasmiditan (Reyvow): 5-HT1F receptor agonist for acute migraine, suitable for patients with cardiovascular contraindications to triptans.

For Patients Dependent on Butalbital

• Fiorinal (Aspirin/Butalbital/Caffeine): Closest pharmacologic equivalent. Note: Schedule III controlled substance.
• Consider a structured taper plan if transitioning away from butalbital entirely
• Preventive therapy (Amitriptyline, Topiramate, or CGRP monoclonal antibodies) may reduce the need for acute butalbital use

For a patient-facing overview of alternatives, you can share our article on alternatives to Acetaminophen/Butalbital.

Tools and Resources for Your Practice

Several resources can help you and your patients navigate the shortage:

• Medfinder for Providers: Real-time pharmacy availability search to help patients locate Acetaminophen/Butalbital in stock
• FDA Drug Shortage Database: Official shortage listings and estimated resolution dates
• ASHP Drug Shortage Resource Center: Clinical guidance and alternative therapy recommendations
• State pharmacy boards: Some states have emergency provisions for prescription transfers during documented shortages

Looking Ahead

The structural factors driving the Acetaminophen/Butalbital shortage — DEA barbiturate manufacturing quotas, a limited number of generic manufacturers, and raw material sourcing challenges — are unlikely to resolve quickly. Providers should:

• Discuss the supply situation proactively with patients who rely on this medication
• Have alternative treatment plans ready for patients who cannot fill prescriptions
• Consider whether patients on chronic butalbital therapy might benefit from transitioning to preventive headache therapies
• Direct patients to availability tools like Medfinder and pricing resources

Final Thoughts

The Acetaminophen/Butalbital shortage represents an ongoing access challenge that disproportionately affects patients with chronic tension headaches. As prescribers, we can mitigate the impact by staying informed about supply trends, maintaining flexible prescribing strategies, and connecting patients with tools to locate and afford their medication.

For more clinical resources, see our provider guide on how to help your patients find Acetaminophen/Butalbital in stock and our upcoming guide on helping patients save money on Acetaminophen/Butalbital.